Overview: PSAP (MLD) TestIntroduction: The PSAP (MLD) Test tests for PSAP gene mutations to diagnose metachromatic leukodystrophy, causing neurological decline, aiding in genetic diagnosis and management. Affecting 1 in 40,000 people, metachromatic leukodystrophy poses diagnostic challenges due to progressive symptoms. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: PSAP Mutation Test, MLD Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: PSAP mutation testing began in the 1990s with research by Gieselmann, who identified the gene. PCR/sequencing advancements by Illumina improved detection, surpassing earlier linkage analysis.
Purpose: Detects PSAP mutation status to diagnose metachromatic leukodystrophy, guides supportive care or gene therapy, and evaluates patients with neurological decline, aiming to manage symptoms.
Test Parameters: PSAP mutation status
Pretest Condition: No special preparation required. Collect whole blood or fibroblasts. Report history of neurological issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Fibroblasts (sterile culture, ~1 cma³); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological decline. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., dementia), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms metachromatic leukodystrophy, guiding care. Early management might slow progression, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: MRI, arylsulfatase A activity, or genetic panel to confirm diagnosis.
Test Limitations: Specific to PSAP; correlation with clinical status needed. False negatives possible with other mutations.
References: NORD Guidelines, 2023; Human Mutation, Gieselmann V, 2022.
